A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms

Journal of Human Genetics

Volumn 50, Issue 9, 2005, Pages 442-447

  Mushiroda, Taisei ^a   Saito, Susumu ^a   Tanaka, Yukiko ^b   Takasaki, Junichi ^a   Kamatani, Naoyuki ^a,c   Beck, Yoshifumi ^b   Tahara, Hideaki ^b   Nakamura, Yusuke ^a,b   Ohnishi, Yozo ^a  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Association study; Cardiotoxicity; Cyclosporine; Genome wide; Prediction score; SNP; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC VARIABILITY; GENOME; GRAFT REJECTION; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PREDICTION; PROGNOSIS; QUALITY OF LIFE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

CALCINEURIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CYCLOSPORINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TACROLIMUS; VARIATION (GENETICS);

EID: 26944458150     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-005-0275-3     Document Type: Article

References (21)

1. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, Volterrani M, Bonetti P, Parrinello G, Cadei M, Grigolato PG, Ferrari R (1999) Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 100:1983-1991
2. Caruso R, Perico N, Cattaneo D, Piccinini G, Bonazzola S, Remuzzi G, Gaspari F (2001) Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem 47:1679-1687
3. Fichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM (2001) Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104:3023-3025
4. Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T (2002) Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet 47:605-610
5. Haug C, Duell T, Lenich A, Kolb HJ, Grunert A (1995) Elevated plasma endothelin concentrations in cyclosporine-treated patients after bone marrow transplantation. Bone Marrow Transplant 16:191-194
6. Hebert SC, Mount DB, Gamba G (2004) Molecular physiology of cation-coupled Cl- cotransport: the SLC12 family. Pflugers Arch 447:580-593
7. Iida A, Sekine A, Saito S, Kitamura Y, Kitamoto T, Osawa S, Mishima C, Nakamura Y (2001) Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. J Hum Genet 46:225-240
8. Kahan BD, Grevel J (1988) Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46:631-644
9. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A (1990) Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 36:1510-1516
10. Margreiter R; European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group (2002) Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: a randomised multicentre study. Lancet 359:741-746
11. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E, et al. (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64:436-443
12. McCaffrey PG, Luo C, Kerppola TK, Jain J, Badalian TM, Ho AM, Burgeon E, Lane WS, Lambert JN, Curran T et al (1993) Isolation of the cyclosporine- sensitive T cell transcription factor NFATp. Science 262:750-754
13. Mount DB, Mercado A, Song L, Xu J, George AL Jr, Delpire E, Gamba G (1999) Cloning and characterization of KCC3 and KCC4, new members of the cation-chloride cotransporter gene family. J Biol Chem 274:16355-16362
14. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y (2001) A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46:471-477
15. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977-983
16. Seino Y, Hori M, Sonoda T (2003) Multicenter prospective investigation on cardiovascular adverse effects of tacrolimus in kidney transplantations. Cardiovasc Drugs Ther 17:141-149
17. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR (1988) Identification of a putative regulator of early T cell activation genes. Science 241:202-205
18. Slowinski T, Subkowski T, Diehr P, Bachert D, Fritsche L, Neumayer HH, Hocher B (2002) Interaction of the endothelin system and calcineurin inhibitors after kidney transplantation. Clin Sci (Lond) 103(Suppl 48):396S-398S
19. Tsunoda T, Lathrop GM, Sekine A, Yamada R, Takahashi A, Ohnishi Y, Tanaka T, Nakamura Y (2004) Variation of gene-based SNPs and linkage disequilibrium patterns in the human genome. Hum Mol Genet 13:1623-1632
20. Weis M, Wildhirt SM, Schulze C, Pehlivanli S, Rieder G, Wolf WP, Wilbert-Lampen U, Meiser BM, Enders G, von Scheidt W (2000) Coronary vasomotor dysfunction in the cardiac allograft: impact of different immunosuppressive regimens. J Cardiovasc Pharmacol 36:776-784
21. + accumulation in myocardial ischaemia of the rabbit. J Physiol 490:215-28